brentuximab vedotin/doxorubicin/vinblastine/dacarbazine (A+AVD)
Jump to navigation
Jump to search
Indications
- antineoplastic combination for treatment of Hodgkin's disease
* superior to ABVD in patients with advanced Hodgkin's disease[1]
* inferior to nivolumab plus AVD in patients with advanced Hodgkin's disease[2]
More general terms
Additional terms
Components
- brentuximab vedotin (Adcetris)
- doxorubicin (Adriamycin, Rubex)
- vinblastine; vincaleukoblastine (Velban, Velsar, Alkaban-AQ)
- dacarbazine (DTIC)
References
- ↑ 1.0 1.1 Connors JM, Jurczak W, Straus DJ et al Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. Dec 10, 2017 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/29224502 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1708984
Longo DL, DeVita DT Jr. Progress in the Treatment of Hodgkin's Lymphoma. N Engl J Med. Dec 10, 2017 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/29224505 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1715141 - ↑ 2.0 2.1 Rutherford SC et al. Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826. J Clin Oncol 2025 Jun 16; [e-pub]. PMID: https://pubmed.ncbi.nlm.nih.gov/40523203 https://ascopubs.org/doi/10.1200/JCO-25-00204